Skip to main content
What types of page to search?

Popular pages: Undergraduate Postgraduate PhD Accommodation Research International students

Alternatively use our A-Z index.

Webinar – New WHO Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable PrEP

Published on

A laptop is open on a table with a mug next to it and a notepad with pen in front of it.

This 60-minute webinar is intended for communities, providers, policy makers and advocates interested in pre-exposure prophylaxis (PrEP), HIV prevention and HIV testing.

We will provide an overview of the key takeaways and guidance from the newly released WHO Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. We also touch on some of the key issues and upcoming plans for lenacapavir implementation.

Objectives

By the end of the webinar, attendees will clearly understand the new WHO recommendations on lenacapavir, the supporting evidence, key implementation considerations, and evidence gaps, empowering them to drive advocacy and informed decisions on the introduction of lenacapavir in countries.

Date and time

Thursday, 28 August 2025

13:00 – 14:00 CEST

Speakers

  • Chair: Michelle Rodolph, WHO headquarters
  • Carlota Baptista da Silva, WHO headquarters
  • Lloyd Mulenga, Ministry of Health, Zambia
  • Danvic Rosadino, Love Yourself, Philippines
  • Heather-Marie Schmidt, UNAIDS
  • Hasina Subedar, National Department of Health, South Africa
  • Olakunle Taiwo, Ministry of Health, Nigeria

For more information and to register, read the original press release.

For more news from the world of long-acting therapeutics, sign up to the CELT's LONGEVITY mailing list here for regular updates.